Purple Biotech Ltd (PPBT) - Cumulative Company Assets

Corporate emblem and logo of Purple Biotech Ltd (PPBT)

Purple Biotech (PPBT) focuses on developing targeted therapies to combat resistant tumors by influencing their microenvironment. This chart reflects an asset value of 24.27, demonstrating the company's total assets. Business resilience depends on the outcomes of tests for pancreatic cancer drugs, while the Israeli management efficiently allocates existing capital to minimize operating expenses.

PPBT: Purple Biotech Ltd Aggregate Company Assets 07/04/2022 - 10/28/2026

Analytical breakdowns for Purple Biotech Corp (PPBT)

- price and consensus price forecast:
Price purple-biotech.com|PPBT - Analyst Consensus Forecast
- market capitalization data:
Market Valuation Kitov Pharma|PPBT - Enterprise Value
- book capitalization data:
Book Value per Share Purple Biotech|PPBT - Company Book Value|Capitalization to Book Value Ratio purple-biotech.com|PPBT - Company Total Assets
- debt and liquidity data:
Total Debt to Equity Ratio Purple Biotech|PPBT - Long-Term Debt to Capital|Current Liabilities to Capital Kitov Pharma|PPBT - Company Debts|Debt to Net Assets Ratio Kitov Pharma
Analysis of all company metrics:PPBT, purple-biotech.com
Manufactured product of Purple Biotech Ltd.

To minimize risks while preserving capital, it is essential to track the total value of Purple Biotech (PPBT) resources and liabilities, which is reverse-calculated via ROA, allowing the scale of the business and the company's fundamental stability to be determined by the total asset value during periods of high pressure on the R&D pipeline while conducting clinical trials for the oncology drugs CM24 and NT219.

Competitors of Purple Biotech (PPBT)

beigene.com (ONC) - Aggregate Business Assets|Company Total Assets HALO|Cumulative Company Assets Revolution Medicines Inc|Company Total Assets AAPG|Company Total Assets CGON (CG Oncology Therapeutics)|URGN - Aggregate Company Assets|Total Business Assets bicara.com BCAX|PSNL: Company Total Assets|ERAS - Cumulative Company Assets|Company Total Assets DCTH|YMAB (Y-mAbs Corp) - Company Assets|AURA - Aggregate Company Assets|Aggregate Asset Value Candel (CADL)|Accuray (ARAY) - Cumulative Company Assets|Aggregate Asset Value sellaslifesciences.com (SLS)|Actuate Therapeutics, Inc - Company Total Assets|CTOR - Cumulative Company Assets|TuHURA - Cumulative Company Assets|TARA: Company Total Assets|Aggregate Company Assets Fate Therapeutics FATE|Aadi Bioscience (WHWK) - Aggregate Asset Value|Company Total Assets TCRX (TScan Therapeutics Inc)|Company Assets CSBR|XBIT - Aggregate Company Assets|Total Asset Value of Company cel-sci.com CVM|Cumulative Company Assets OSTX (OS Therapies)|radiopharmtheranostics.com - Company Total Assets|Aggregate Company Assets Artiva (ARTV)|ANL: Aggregate Asset Value|Aggregate Company Assets Veru Inc. (VERU)|TPST (tempesttx.com) - Total Asset Value of Company|Aggregate Company Assets Xilio Therapeutics Inc|Aggregate Company Assets Enochian BioSciences|Mural Oncology plc - Company Total Assets|Company Assets kairospharma.com KAPA|Cumulative Company Assets OnKure Therapeutics|Aggregate Asset Value CytoMed Therapeutics Ltd GDTC|CRIS - Company Total Assets|APLM - Aggregate Company Assets|Tharimmune Corp - Company Total Assets|ADVB (Advanced Biomed) - Company Total Asset Base|Aggregate Company Assets GNPX (Genprex, Inc.)|Company Assets Calidi Bio (CLDI)|Cumulative Company Assets Sunshine Biopharma, Inc.|Aggregate Business Assets xeneticbio.com (XBIO)|SLRX: Company Total Assets|Company Assets American Oncology Network Inc AONC|BGNE: Company Total Assets|CKPT - Cumulative Company Assets|Company Total Assets Elevation Oncology ELEV|ICAD (iCAD) - Aggregate Asset Value|Aggregate Company Assets Ikena Oncology Inc. IKNA|Total Asset Value of Company NTBL|VIRX - Aggregate Company Assets|Total Asset Value of Company morphosys.com (MOR)|Company Total Assets NAYA Biosciences Inc. NAYA|AAPGV - Aggregate Company Assets